Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial

计划入组 60 人 · 首次发布于 2025 年 3 月 28 日

Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients

计划入组 180 人 · 首次发布于 2025 年 8 月 26 日

Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease

计划入组 8,020 人 · 首次发布于 2009 年 10 月 15 日

undisclosed compounds (bone disorders)

Mineral oil(Fleet Mineral Oil, Lubrifresh P.M., Meijer, Preparation H Reformulated Jun 2013, Refresh Lacri-lube, Refresh PM, Retaine Mgd, Soothe Mineral Oil, Soothe Night Time, Stye, Systane, Systane Nighttime, Tears Again Ointment)

LGR4 modulators (cancer/bone disorders)

Si-Bone

United States

Bone Biologics

Bone Therapeutics

Belgium

EMA Recommends Approval of Averoa's XOANACYL for Chronic Kidney Disease Treatment

Menopausal Hormone Therapy Associated with 69% Reduced Odds of Low Bone Mineral Density in Postmenopausal Women

Amgen's MariTide Obesity Drug Candidate Faces Scrutiny Over Bone Mineral Density Concerns